Search results for "cellular"

showing 10 items of 6449 documents

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

2021

Summary Background Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection. Aims We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure. Methods Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated. Results No bleeding complication was reported. One and two liver failures were respect…

medicine.medical_specialtyCarcinoma HepatocellularNeutropeniaurologic and male genital diseasesPlaceboPlacebo groupGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansChemoembolization TherapeuticHepatologybusiness.industrySunitinibLiver NeoplasmsGastroenterologyLiver failuremedicine.diseaseAcute toxicityTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDose reductionbusinessLiver Failuremedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis

2020

Occult metastasis from the initial tumor and a de novo second primary hepatocellular carcinoma (HCC) were recognized as the main causes for the onset of early and late HCC recurrence, after liver resection (LR). This study aims to compare the time to recurrence after LR for HCC in which a margin ≤ 1 mm or > 1 mm was achieved. A single-center retrospective study involving 256 patients was conducted from June 2005 to June 2019. HCC patients resected with a radical surgical approach were investigated and stratified into groups A (resection margins ≤ 1 mm) and B (> 1 mm), as measured on final pathologic assessment. Kaplan–Meier estimators were used to estimate the probability of recurrenc…

medicine.medical_specialtyCarcinoma HepatocellularTime FactorsHepatocellular carcinomaHepatocellular carcinoma; Liver resection; Liver transplantation; Margin status; Outcome030230 surgerySingle CenterGastroenterologyGroup BMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHepatocellular carcinoma Liver resection Liver transplantation Margin status Outcome Carcinoma Hepatocellular Liver Neoplasms Neoplasm Recurrence Local Neoplasms Second Primary Time Factors Hepatectomy Margins of ExcisionEpidemiologyHepatectomyHumansMedicineMargin statusPathologicalOutcomeLiver transplantationLiver resectionbusiness.industryProportional hazards modelLiver NeoplasmsMargins of ExcisionNeoplasms Second PrimaryRetrospective cohort studymedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

2007

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A stri…

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive diseaseTransplantation Proceedings
researchProduct

Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis

2020

Hepatocellular carcinoma (HCC) is frequently associated with macrovascular invasion of the portal vein or hepatic veins in advanced stages. The accurate diagnosis of macrovascular invasion and the differentiation from bland non-tumoral thrombus has significant clinical and management implications, since it narrows the therapeutic options and it represents a mandatory con-traindication for liver resection or transplantation. The imaging diagnosis remains particularly challenging since the imaging features of HCC with macrovascular invasion may be subtle, espe-cially in lesions showing infiltrative appearance. However, each radiologic imaging modality may provide findings suggesting the prese…

medicine.medical_specialtyCarcinoma Hepatocellularendocrine system diseasesMultimodal Imaging030218 nuclear medicine & medical imagingResection03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansImaging diagnosisAbdominal ImagingRadiology Nuclear Medicine and imagingcardiovascular diseasesThrombusContraindicationSettore MED/12 - GastroenterologiaPortal Veinbusiness.industryLiver NeoplasmsAdvanced stagemedicine.diseaseTransplantationManagement implicationsHepatocellular carcinomacardiovascular systemRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiaCardiology and Cardiovascular MedicinebusinessDiagnostic and Interventional Radiology
researchProduct

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.

2010

Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomized controlled trials (RCTs) of new therapeutic approaches; however, survival of patients in the absence of treatment is highly variable, and prognostic factors influencing outcomes are incompletely defined. The aims of this meta-analysis were to estimate the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of palliative treatments, and to identify prognostic factors. RCTs evaluating therapies for HCC with placebo or no-treatment arms were identified on MEDLINE through April 2009. Data were combined in a random effect model. Primary outcomes were 1-year and 2-year s…

medicine.medical_specialtyCarcinoma Hepatocellularlaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemoembolization TherapeuticSurvival rateNeoplasm StagingRandomized Controlled Trials as TopicHepatologyPerformance statusbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseConfidence intervalSurgerySurvival RateMeta-analysisHepatocellular carcinomaRegression AnalysisLiver cancerbusinessPublication BiasHepatology (Baltimore, Md.)
researchProduct

Expression of Wild-Type and Variant Estrogen Receptor Alpha in Liver Carcinogenesis and Tumor Progression.

2011

Although estrogen receptors (ERs) are expressed in human hepatocellular carcinoma (HCC), several clinical trials have failed to demonstrate the efficacy of antiestrogen treatment in HCC patients. Recently, the identification of several ER splicing variants has enlightened the complex nature of estrogen signaling in peripheral tissues; this may help understanding estrogen role in either nontumoral or malignant nonclassical target organs, including liver. In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reacti…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEstrogen receptorBiologyBiochemistryAromataseCell Line TumorInternal medicineGene OrderGeneticsmedicineHumansRNA MessengerneoplasmsMolecular BiologyLiver NeoplasmsEstrogen Receptor alphaWild typeExonsHep G2 Cellsmedicine.diseaseAntiestrogenGene Expression Regulation NeoplasticReverse transcription polymerase chain reactionAlternative SplicingCell Transformation NeoplasticEndocrinologyLiverEstrogenTumor progressionHepatocellular carcinomaCancer researchMolecular MedicineEstrogen receptor alphaLiver carcinogenesis Estrogen receptors tumor progressionBiotechnology
researchProduct

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

2019

BACKGROUND: The recurrence of hepatocellular carcinoma (HCC) is the strongest survival-limiting factor after liver transplantation (LT) in patients with HCC. In the face of donor organ shortage, it is necessary to identify factors associated with HCC recurrence in order to maximize the utility of the available grafts. OBJECTIVE: To study the phenomenon of HCC recurrence after LT at a European transplantation centre over the past 20 years. METHODS: Data from 304 HCC patients who underwent LT were prospectively recorded. Clinical and pathological factors were assessed for their association with recurrence. RESULTS: Fifty-one patients (16.8%) had HCC recurrence after LT. Patients exceeding the…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentEconomic shortageLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansIn patientneoplasmsProportional Hazards Modelsbusiness.industryLiver NeoplasmsGastroenterologyOriginal Articlesmedicine.diseasePrognosisdigestive system diseasesLiver TransplantationTransplantationEuropeTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessLiver cancer
researchProduct

Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver re…

2016

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentTreatment outcomeResection03 medical and health sciences0302 clinical medicineText miningResectable Hepatocellular CarcinomamedicinePathologic ResponseHepatectomyHumansChemoembolization TherapeuticRetrospective StudiesHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRadiologyHepatectomyNeoplasm Recurrence LocalbusinessHepatobiliarypancreatic diseases international : HBPD INT
researchProduct

Endothelial Cell Swelling and Brain Perfusion

1997

Background: Whereas the contribution of glial swelling to no-reflow conditions in the ischemic penumbra or during reperfusion after global ischemia is widely discussed, little is known about cell volume control of endothelial cells under reperfusion conditions. Methods: The effect of extracellular acidosis-a key mediator of secondary brain damage-on cell volume was studied in the GM7373 endothelial cell line. Experiments were performed at pH = 6.0 in the presence or absence of bicarbonate, and during exposure to inhibitors of specific transport systems such as ethyl isopropyl amiloride or 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid. Results: Endothelial swelling to 111.1 ± 3.4% was f…

medicine.medical_specialtyCell Membrane PermeabilityBicarbonateIschemiaPharmacologyBrain IschemiaCell Linechemistry.chemical_compoundmedicineExtracellularAnimalsCell Sizebusiness.industryMicrocirculationPenumbraHydrogen-Ion Concentrationmedicine.diseaseAmilorideSurgeryEndothelial stem cellchemistryCerebrovascular CirculationReperfusion InjuryCattleEndothelium VascularSwellingmedicine.symptomAcidosisbusinessIsopropylmedicine.drugThe Journal of Trauma: Injury, Infection, and Critical Care
researchProduct